癫痫克星！首个辅助治疗癫痫液体制剂Zonisade获批上市

Epilepsy is a common disease of the nervous system, and about 40% of epilepsy patients develop the disease before the age of 16 [1]. Epilepsy is a group of chronic brain diseases with transient central nervous system dysfunction caused by abnormal discharge of brain nerves. It is a common central nervous system disease. The treatment of epilepsy mainly includes etiological treatment, drug treatment, psychological treatment, etc. [2]. Recently, Azurity Pharmaceuticals, Inc. announced that the U.S. FDA has newly approved Zonisade (zonisamide oral suspension, zonisamide) as an adjuvant treatment for the treatment of partial seizures in adults and adolescents with epilepsy aged 16 years and above.

(pixabay)

Zonisade is the first liquid formulation approved by the FDA for auxiliary epilepsy

Currently, Zonisade is the first and only oral liquid formulation of zonisamide approved by the U.S. Food and Drug Administration (FDA). Its arrival brings therapeutic benefits to some patients with epilepsy. As adjunctive therapy for the treatment of partial-onset seizures in adults and adolescents with epilepsy aged 16 years and older. The efficacy and tolerability of zonisamide oral suspension have been demonstrated in three double-blind, placebo-controlled, multicenter clinical trials. Zonisade dosage should be administered once or twice daily. However, the efficacy and safety of Zonisade in adolescent patients under the age of 16 have not yet been determined, and we look forward to good clinical trial data in the near future.

Trivia: At what stage does a person suffer from epilepsy?

① New cases of epilepsy are most common in children, especially in the first year of life.

②The rate of new cases of epilepsy gradually decreases until about 10 years old, and then stabilizes.

③After the age of 55, the incidence of new cases of epilepsy begins to increase as people develop strokes, brain tumors, or Alzheimer's disease, which can lead to epilepsy.

Other epilepsy medicines Vibatrin may be used as adjunctive treatment in adults and infants

The original drug Vigabatrin (aminoenoic acid) is suitable for patients with epilepsy. As early as 2009, Vigabatrin has been approved by the US FDA for the treatment of infantile spasms and complex partial epilepsy. The main target groups are:

1. Vigabatrin can be used as an auxiliary treatment for partial seizures of refractory complex epilepsy.

2. Vigabatrin can also be used to treat infantile spasms and Lennox-Gastaut syndrome.

In recent years, many scholars have discovered that epileptic seizures have certain biological rhythms. Different parts of epilepsy and different types of epilepsy have different seizure frequencies in different states and at different times. Therefore, once you find signs of epilepsy, you should go to the hospital for diagnosis and treatment as soon as possible and take medication to control it to achieve the best treatment effect.

References

[1] Zhu Dongyu, Lu Lingdan, Xu Qiang, Lu Zhengyu, Zhao Hong. Treatment and health education of adolescent epilepsy [J]. Health Education and Health Promotion, 2016, 11(01): 36-38. DOI: 10.16117/j.cnki.31-1974/r.201601012.

[2] Xu Lijuan, Wu Jiayong, Wang Chong. Progress in the treatment of adolescent epilepsy [J]. International Journal of Neurology and Neurosurgery, 2015, 42(04): 355-358.DOI: 10.16636/j.cnki.jinn.2015.04.010.

[3]AZURITYPHARMACEUTICALS,INC.ANNOUNCESFDAAPPROVALOFZONISADE™(zonisamideoralsuspension)

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.